NSRX
Nasus Pharma Ltd. · AMEX
- Market cap
- $33.6M
Nasus Pharma Ltd. (NSRX) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. In the last 30 days Quantisnow tracked 3 wire items for NSRX, including 1 SEC filing, 1 press release or news item and 1 insider trade. The most recent was published Nov 14, 2026.
Financial highlights
Full financials- Revenue, FY2025
- $1.24B
- Net income, FY2025
- -$5.86M
- Net margin
- -0.5%
- Free cash flow, FY2025
- -$4.93M
- Cash
- $1.24M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks33-33%
2026-05-242026-11-15
Mix2090d
- SEC Filings10(50%)
- Other6(30%)
- Insider3(15%)
- Earnings1(5%)
Activity · 52 weeks7953 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERChief Executive Officer O'Grady Brendan P. was granted 210,000 share options (SEC Form 4)4 - Nasus Pharma Ltd (0002029039) (Issuer)
- PRNasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026TEL AVIV, Israel, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that abstracts supporting NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, have been accepted for presentation at the upcoming the American College of Allergy, Asthma & Immunology ("ACAAI") 2026 Annual Scientific Meeting, to be held in Phoenix, AZ November 12-16, 2026. The abstract Enhanced Absorption of Intranasal Powder Epinephrine (FMXIN002) after Single Dose in Adults with Allergic Rhinitis (8032) was selected fo
- SECSEC Form S-8 filed by Nasus Pharma Ltd.S-8 - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of OndansetronTEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 pharmacokinetic (PK) trial of NS003, its proprietary intranasal powder formulation of ondansetron being developed for chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). In a recent pre-clinical study comparing NS003 to the intravenous ("IV") formulation of ondansetron in animals, results showed that NS003 had a PK profile comparable to the
- INSIDERSEC Form 3 filed by new insider Elmaliah Oren3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Rubin Eyal4 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form 424B5 filed by Nasus Pharma Ltd.424B5 - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of AnaphylaxisClinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027 TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational
- SECSEC Form EFFECT filed by Nasus Pharma Ltd.EFFECT - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceTEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel. The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal Rubin, Chief Financial Officer, will be available for one-on-one
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form F-3 filed by Nasus Pharma Ltd.F-3 - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form EFFECT filed by Nasus Pharma Ltd.EFFECT - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Announces Transition of Chief Financial OfficerTEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer. "I have known Eyal for over a decade and have always admired his con
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Reports First Half 2026 Financial Results and Provides Business UpdateAppointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced its financial results for the six months ending June 30, 2026 and provided a corporate update. "Nasus has made enormous progress in its clinical programs in the first six months of 2026, and we believe it is well positioned to advance to NS002 and NS003 toward key milestones in the second hal
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nasus Pharma Ltd.SCHEDULE 13G/A - Nasus Pharma Ltd (0002029039) (Subject)
- INSIDERSEC Form 3 filed by new insider O'Grady Brendan P.3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Teleman Dan Benjamin4 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic GrowthTEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady will lead the Company's next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company's pipeline and business development initiatives, and maximizing the value of its proprietary Nasax® intranasal technology platform. Mr. O'Grady succeeds Dan Teleman, with the leadership transition effective Jul
NSRX FAQ
9 questionsWhat is the latest news on NSRX?
In the last 30 days Quantisnow tracked 3 wire items for NSRX: 1 SEC filing, 1 press release or news item and 1 insider trade. The most recent was published on November 14, 2026.What is NSRX revenue?
Nasus Pharma Ltd. (NSRX) reported $1.24B of revenue for fiscal 2025 (ended Dec 31, 2025).Is NSRX profitable?
No. Nasus Pharma Ltd. reported a net loss of $5.86M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NSRX have?
Nasus Pharma Ltd. reported $1.24M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NSRX stock trade?
Nasus Pharma Ltd. (NSRX) is listed on AMEX.What sector and industry is NSRX in?
Nasus Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nasus Pharma Ltd. go public?
Nasus Pharma Ltd. (NSRX) completed its IPO in 2025.What companies are similar to NSRX?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare NSRX side-by-side with any of them on Quantisnow.How can I track NSRX on Quantisnow?
Quantisnow aggregates Nasus Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NSRX to receive live email and push alerts on every new disclosure.